Intensification of medical management in type 2 diabetes: A real-world look at primary care practice

Kidmealem Zekarias; Cynthia Davey; Elizabeth Seaquist

doi:10.1016/j.jdiacomp.2019.107477

Intensification of medical management in type 2 diabetes: A real-world look at primary care practice

Kidmealem Zekarias, Cynthia Davey, Elizabeth Seaquist

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

AIMS: To determine which drugs were selected to be added to metformin for patients on dual anti-diabetic medication in the management of type 2 diabetes and to assess HbA1c and BMI outcomes at 6 and 12 months after the initiation of a second anti-diabetic medication.

METHODS: A retrospective chart review of electronic medical record data. Second line anti-diabetic medication added to metformin between 7/1/2012 to 8/31/2017 in the primary care practice in Fairview Health System in Minnesota.

RESULTS: 3413 patients met the selection criteria of type 2 diabetes, 18 years and older, dual anti-diabetes therapy with metformin being the first prescribed. The most frequently prescribed medications added to metformin were sulfonylurea and basal insulin accounting for 51% (1724/3413) and 37% (1268/3413) respectively. Mean HbA1c reductions at 6 and 12 months among 2134 patients with baseline and follow-up HbA1c data respectively were: GLP-1 agonist (-1.3, P < 0.001; -1.2, P < 0.001), sulfonylurea (-1.1, P < 0.001; -0.9, P < 0.001), basal insulin (-1.1, P < 0.001; -1.0, P < 0.001), DPP4 inhibitor (-0.7, P = 0.223; -0.8, P = 0.049). Patients prescribed a GLP-1 agonist had a higher mean baseline BMI (BMI =40.3 kg/m 2) and this was the only group with a statistically significant BMI reduction from baseline at 6 and 12 months (-1.5, P = 0.049 and -1.8, P = 0.041).

CONCLUSION AND RELEVANCE: Type 2 diabetes patients treated with sulfonylurea, basal insulin and GLP-1 agonist as an add on to metformin had significant reductions in HbA1c. Patients prescribed a GLP-1 agonist had a significant BMI reduction.

Original language	English (US)
Article number	107477
Journal	Journal of Diabetes and Its Complications
Volume	34
Issue number	1
DOIs	https://doi.org/10.1016/j.jdiacomp.2019.107477
State	Published - Jan 2020

Bibliographical note

Funding Information:
The authors would like to thank the Informatics Consulting Service of the Clinical and Translational Science Institute of the University of Minnesota and the Fairview Health services. Funding was provided by institutional funds to Dr. Seaquist. This research was supported by the National Institutes of Health 's National Center for Advancing Translational Sciences, grant UL1TR002494 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Center for Advancing Translational Sciences.

Funding Information:
The authors declare that there are no conflicts of interest. Dr. Elizabeth Seaquist serves as a consultant for Lilly, Sanofi, MannKind, Zucara, and WebMD. The University that employs Dr. Seaquist has accepted research funding from Lilly to support her work.The authors would like to thank the Informatics Consulting Service of the Clinical and Translational Science Institute of the University of Minnesota and the Fairview Health services. Funding was provided by institutional funds to Dr. Seaquist. This research was supported by the National Institutes of Health's National Center for Advancing Translational Sciences, grant UL1TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Center for Advancing Translational Sciences.

Publisher Copyright:
© 2019

PubMed: MeSH publication types

Journal Article
Research Support, N.I.H., Extramural

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.jdiacomp.2019.107477

Find It

Find It at U of M Libraries

Cite this

@article{1a44fc9988ff4a5382e4c74601bf1427,

title = "Intensification of medical management in type 2 diabetes: A real-world look at primary care practice",

abstract = "AIMS: To determine which drugs were selected to be added to metformin for patients on dual anti-diabetic medication in the management of type 2 diabetes and to assess HbA1c and BMI outcomes at 6 and 12 months after the initiation of a second anti-diabetic medication.METHODS: A retrospective chart review of electronic medical record data. Second line anti-diabetic medication added to metformin between 7/1/2012 to 8/31/2017 in the primary care practice in Fairview Health System in Minnesota.RESULTS: 3413 patients met the selection criteria of type 2 diabetes, 18 years and older, dual anti-diabetes therapy with metformin being the first prescribed. The most frequently prescribed medications added to metformin were sulfonylurea and basal insulin accounting for 51% (1724/3413) and 37% (1268/3413) respectively. Mean HbA1c reductions at 6 and 12 months among 2134 patients with baseline and follow-up HbA1c data respectively were: GLP-1 agonist (-1.3, P < 0.001; -1.2, P < 0.001), sulfonylurea (-1.1, P < 0.001; -0.9, P < 0.001), basal insulin (-1.1, P < 0.001; -1.0, P < 0.001), DPP4 inhibitor (-0.7, P = 0.223; -0.8, P = 0.049). Patients prescribed a GLP-1 agonist had a higher mean baseline BMI (BMI =40.3 kg/m 2) and this was the only group with a statistically significant BMI reduction from baseline at 6 and 12 months (-1.5, P = 0.049 and -1.8, P = 0.041). CONCLUSION AND RELEVANCE: Type 2 diabetes patients treated with sulfonylurea, basal insulin and GLP-1 agonist as an add on to metformin had significant reductions in HbA1c. Patients prescribed a GLP-1 agonist had a significant BMI reduction.",

author = "Kidmealem Zekarias and Cynthia Davey and Elizabeth Seaquist",

note = "Funding Information: The authors would like to thank the Informatics Consulting Service of the Clinical and Translational Science Institute of the University of Minnesota and the Fairview Health services. Funding was provided by institutional funds to Dr. Seaquist. This research was supported by the National Institutes of Health 's National Center for Advancing Translational Sciences, grant UL1TR002494 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Center for Advancing Translational Sciences. Funding Information: The authors declare that there are no conflicts of interest. Dr. Elizabeth Seaquist serves as a consultant for Lilly, Sanofi, MannKind, Zucara, and WebMD. The University that employs Dr. Seaquist has accepted research funding from Lilly to support her work.The authors would like to thank the Informatics Consulting Service of the Clinical and Translational Science Institute of the University of Minnesota and the Fairview Health services. Funding was provided by institutional funds to Dr. Seaquist. This research was supported by the National Institutes of Health's National Center for Advancing Translational Sciences, grant UL1TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Center for Advancing Translational Sciences. Publisher Copyright: {\textcopyright} 2019",

year = "2020",

month = jan,

doi = "10.1016/j.jdiacomp.2019.107477",

language = "English (US)",

volume = "34",

journal = "Journal of Diabetes and its Complications",

issn = "1056-8727",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Intensification of medical management in type 2 diabetes

T2 - A real-world look at primary care practice

AU - Zekarias, Kidmealem

AU - Davey, Cynthia

AU - Seaquist, Elizabeth

N1 - Funding Information: The authors would like to thank the Informatics Consulting Service of the Clinical and Translational Science Institute of the University of Minnesota and the Fairview Health services. Funding was provided by institutional funds to Dr. Seaquist. This research was supported by the National Institutes of Health 's National Center for Advancing Translational Sciences, grant UL1TR002494 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Center for Advancing Translational Sciences. Funding Information: The authors declare that there are no conflicts of interest. Dr. Elizabeth Seaquist serves as a consultant for Lilly, Sanofi, MannKind, Zucara, and WebMD. The University that employs Dr. Seaquist has accepted research funding from Lilly to support her work.The authors would like to thank the Informatics Consulting Service of the Clinical and Translational Science Institute of the University of Minnesota and the Fairview Health services. Funding was provided by institutional funds to Dr. Seaquist. This research was supported by the National Institutes of Health's National Center for Advancing Translational Sciences, grant UL1TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Center for Advancing Translational Sciences. Publisher Copyright: © 2019

PY - 2020/1

Y1 - 2020/1

N2 - AIMS: To determine which drugs were selected to be added to metformin for patients on dual anti-diabetic medication in the management of type 2 diabetes and to assess HbA1c and BMI outcomes at 6 and 12 months after the initiation of a second anti-diabetic medication.METHODS: A retrospective chart review of electronic medical record data. Second line anti-diabetic medication added to metformin between 7/1/2012 to 8/31/2017 in the primary care practice in Fairview Health System in Minnesota.RESULTS: 3413 patients met the selection criteria of type 2 diabetes, 18 years and older, dual anti-diabetes therapy with metformin being the first prescribed. The most frequently prescribed medications added to metformin were sulfonylurea and basal insulin accounting for 51% (1724/3413) and 37% (1268/3413) respectively. Mean HbA1c reductions at 6 and 12 months among 2134 patients with baseline and follow-up HbA1c data respectively were: GLP-1 agonist (-1.3, P < 0.001; -1.2, P < 0.001), sulfonylurea (-1.1, P < 0.001; -0.9, P < 0.001), basal insulin (-1.1, P < 0.001; -1.0, P < 0.001), DPP4 inhibitor (-0.7, P = 0.223; -0.8, P = 0.049). Patients prescribed a GLP-1 agonist had a higher mean baseline BMI (BMI =40.3 kg/m 2) and this was the only group with a statistically significant BMI reduction from baseline at 6 and 12 months (-1.5, P = 0.049 and -1.8, P = 0.041). CONCLUSION AND RELEVANCE: Type 2 diabetes patients treated with sulfonylurea, basal insulin and GLP-1 agonist as an add on to metformin had significant reductions in HbA1c. Patients prescribed a GLP-1 agonist had a significant BMI reduction.

AB - AIMS: To determine which drugs were selected to be added to metformin for patients on dual anti-diabetic medication in the management of type 2 diabetes and to assess HbA1c and BMI outcomes at 6 and 12 months after the initiation of a second anti-diabetic medication.METHODS: A retrospective chart review of electronic medical record data. Second line anti-diabetic medication added to metformin between 7/1/2012 to 8/31/2017 in the primary care practice in Fairview Health System in Minnesota.RESULTS: 3413 patients met the selection criteria of type 2 diabetes, 18 years and older, dual anti-diabetes therapy with metformin being the first prescribed. The most frequently prescribed medications added to metformin were sulfonylurea and basal insulin accounting for 51% (1724/3413) and 37% (1268/3413) respectively. Mean HbA1c reductions at 6 and 12 months among 2134 patients with baseline and follow-up HbA1c data respectively were: GLP-1 agonist (-1.3, P < 0.001; -1.2, P < 0.001), sulfonylurea (-1.1, P < 0.001; -0.9, P < 0.001), basal insulin (-1.1, P < 0.001; -1.0, P < 0.001), DPP4 inhibitor (-0.7, P = 0.223; -0.8, P = 0.049). Patients prescribed a GLP-1 agonist had a higher mean baseline BMI (BMI =40.3 kg/m 2) and this was the only group with a statistically significant BMI reduction from baseline at 6 and 12 months (-1.5, P = 0.049 and -1.8, P = 0.041). CONCLUSION AND RELEVANCE: Type 2 diabetes patients treated with sulfonylurea, basal insulin and GLP-1 agonist as an add on to metformin had significant reductions in HbA1c. Patients prescribed a GLP-1 agonist had a significant BMI reduction.

UR - http://www.scopus.com/inward/record.url?scp=85075495427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075495427&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2019.107477

DO - 10.1016/j.jdiacomp.2019.107477

M3 - Article

C2 - 31711841

AN - SCOPUS:85075495427

VL - 34

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 1

M1 - 107477

ER -

Intensification of medical management in type 2 diabetes: A real-world look at primary care practice

Abstract

Bibliographical note

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this